SMARCB1deficient

SMARCB1 (SWI–SNF related matrix-associated actin-dependent regulator of chromatin subfamily B member 1), also known as INI1 or SNF5, encodes a core subunit of the SWI‑SNF chromatin remodeling complex that modulates transcription, cell cycle progression, and differentiation. The protein binds to histone H2A–H2B dimers and recruits coactivators or corepressors, influencing nucleosome positioning on target gene loci.

Deficiency of SMARCB1 refers to loss‐of‐function mutations, homozygous deletions, or epigenetic silencing that reduce or eliminate protein expression. The deficiency can be inherited in an autosomal dominant manner (with germline heterozygous mutations predisposing to familial cancer syndromes) or occur sporadically in somatic cells. In tumor cells, biallelic inactivation of SMARCB1 leads to unchecked proliferation and impaired differentiation.

The most clinically studied consequence of SMARCB1 loss is atypical teratoid/rhabdoid tumor (AT/RT) of the brain, a highly malignant neoplasm of infancy and early childhood. Other tumors frequently harbor SMARCB1 deficiency, including malignant rhabdoid tumors of extra‑central nervous system sites, renal medullary carcinoma, epithelioid sarcoma, and certain subsets of osteosarcomas and gastrointestinal stromal tumors. SMARCB1 loss is a diagnostic marker in many of these malignancies, guiding pathological classification and prognostication.

Diagnosis of SMARCB1 deficiency relies on immunohistochemistry to detect loss of INI1 protein in tumor nuclei, supplemented by fluorescence in situ hybridization (FISH) or next‑generation sequencing to identify deletions or point mutations. Quantitative mRNA analysis may also reveal reduced transcript levels. Routine screening for SMARCB1 status is recommended in tumors where its loss defines the entity, such as AT/RT and epithelioid sarcoma.

Therapeutic options for SMARCB1‑deficient cancers remain limited, but emerging strategies target epigenetic vulnerabilities, such as EZH2 inhibition, BRD4 bromodomain blockade, or PARP inhibition. Immunotherapies including checkpoint blockade have shown variable efficacy. Preclinical studies continue to uncover synthetic lethal interactions exploitable for drug development. Ongoing research into the molecular consequences of SMARCB1 loss seeks to improve diagnostic precision and expand targeted treatment avenues for affected patients.